Syncromune® Inc. Expands Scientific Advisory Board with Addition of Prominent Oncology Trailblazer James Armitage, M.D.Dr. Armitage is a world-renowned expert in the research and treatment of lymphoma and will serve as Advisory Board ChairOctober 31, 2023 08:00 AM Eastern Daylight Time FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Syncromune®, Inc., a clinical-stage biopharmaceutical company focused on...
Category: 2023
Eucure and Syncromune Establish Technology Transfer Agreement for YH002 (OX40 Antibody) and Multiple Other Clinical-Stage Antibodies
Eucure and Syncromune Establish Technology Transfer Agreement for YH002 (OX40 Antibody) and Multiple Other Clinical-Stage AntibodiesBEIJING, China, August 30, 2023 – Eucure (Beijing) Biopharma Co., Ltd. (“Eucure”), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”), announced today that the company has entered into a technology transfer agreement with...
Syncromune® Inc., Appoints Jonathan Lewis, M.D., Ph.D., A Renowned Immune Therapy Pioneer, as Chief Medical Officer
Syncromune® Inc., Appoints Jonathan Lewis, M.D., Ph.D., A Renowned Immune Therapy Pioneer, as Chief Medical OfficerFORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Syncromune, Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, a groundbreaking platform technology that synchronizes in situ neoantigen T cell education and immunostimulation via a drug/device combination therapy, proudly announces the appointment...
